Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention...

Area of Science:

• Genetics and Cardiovascular Disease
• Pharmacogenomics
• Preventive Medicine

Background:

• Cardiovascular disease (CVD) prevention often involves aspirin.
• Genetic variations, such as in the guanylate cyclase GUCY1A3 gene, may influence aspirin's efficacy.
• The GUCY1A3 rs7692387 risk (G) allele is associated with increased CVD risk.

Purpose of the Study:

• To investigate the impact of GUCY1A3 genotype on aspirin's effectiveness in primary CVD prevention.
• To determine if individuals homozygous for the GUCY1A3 risk allele benefit from aspirin therapy.
• To assess aspirin's effect on both CVD events and bleeding risk across different GUCY1A3 genotypes.

Main Methods:

• Analysis of two large randomized placebo-controlled trials: Women's Genome Health Study (WGHS) and Physician's Health Study (PHS).
• Genotyping for the GUCY1A3 rs7692387 allele.
• Statistical analysis including meta-analysis to evaluate CVD event incidence and bleeding risk based on genotype and aspirin use.

Main Results:

• The GUCY1A3 risk (G) allele was confirmed to increase CVD risk in placebo groups.
• Aspirin reduced CVD events in individuals homozygous for the GUCY1A3 risk allele (G/G).
• Aspirin increased CVD events in non-risk allele carriers (G/A heterozygotes), indicating a significant interaction (Pinteraction = 0.01).
• Bleeding risk associated with aspirin increased across all genotype groups, notably in heterozygotes.

Conclusions:

• Aspirin's efficacy in primary CVD prevention is genotype-dependent, specifically influenced by the GUCY1A3 rs7692387 allele.
• Individuals homozygous for the GUCY1A3 risk allele may benefit from aspirin for CVD prevention.
• Heterozygotes carrying the GUCY1A3 risk allele may experience increased CVD events with aspirin use, warranting further investigation.